OBJECTIVE: The prevalence of depressive symptoms is high in patients with systemic sclerosis (SSc, scleroderma). This study was conducted to determine which disease-related and psychosocial factors are associated with depressive symptoms, independent of sociodemographic factors. METHODS: In total, 215 patients with SSc completed questionnaires on sociodemographics, physical functioning (HAQ-DI), pain (VAS), fatigue (CIS), psychosocial characteristics (CISS, ICQ, PRQ, ASE, FoP-Q-SF) and depressive symptoms (CES-D). Disease characteristics (disease duration, disease subtype, modified Rodnan Skin Score) were collected. Hierarchical linear regression analyses were conducted to assess associations with depressive symptoms. RESULTS: The mean CES-D score was 12.9 (SD=9.7) and the prevalence of patients scoring>= 16 and>=19 were 32.1% and 25.1%, respectively. The variance explained by sociodemographics and disease characteristics was negligible (R(2)≤.09). Fatigue and pain were independently associated with depressive symptoms (R(2) change=.35). After adding psychological factors (R(2) change=.21), satisfaction with social support, emotion-focused coping and helplessness were also significantly associated with depressive symptoms. Higher fear of progression was associated with more depressive symptoms (P≤.01), and appearance self-esteem showed a marginally significant association (P=.08). CONCLUSION: Depressive symptoms were common in the present sample of patients with SSc and were independently associated with pain, fatigue, social support, emotion-focused coping, helplessness and fear of progression. Results suggest that, in addition to assessment of disease characteristics, attention should be given also to psychosocial factors found to be associated with depressive symptoms. For the development and trialling of psychological interventions, fear of progression could be an important target.
OBJECTIVE: The prevalence of depressive symptoms is high in patients with systemic sclerosis (SSc, scleroderma). This study was conducted to determine which disease-related and psychosocial factors are associated with depressive symptoms, independent of sociodemographic factors. METHODS: In total, 215 patients with SSc completed questionnaires on sociodemographics, physical functioning (HAQ-DI), pain (VAS), fatigue (CIS), psychosocial characteristics (CISS, ICQ, PRQ, ASE, FoP-Q-SF) and depressive symptoms (CES-D). Disease characteristics (disease duration, disease subtype, modified Rodnan Skin Score) were collected. Hierarchical linear regression analyses were conducted to assess associations with depressive symptoms. RESULTS: The mean CES-D score was 12.9 (SD=9.7) and the prevalence of patients scoring>= 16 and>=19 were 32.1% and 25.1%, respectively. The variance explained by sociodemographics and disease characteristics was negligible (R(2)≤.09). Fatigue and pain were independently associated with depressive symptoms (R(2) change=.35). After adding psychological factors (R(2) change=.21), satisfaction with social support, emotion-focused coping and helplessness were also significantly associated with depressive symptoms. Higher fear of progression was associated with more depressive symptoms (P≤.01), and appearance self-esteem showed a marginally significant association (P=.08). CONCLUSION:Depressive symptoms were common in the present sample of patients with SSc and were independently associated with pain, fatigue, social support, emotion-focused coping, helplessness and fear of progression. Results suggest that, in addition to assessment of disease characteristics, attention should be given also to psychosocial factors found to be associated with depressive symptoms. For the development and trialling of psychological interventions, fear of progression could be an important target.
Authors: Leticia Leon; Lydia Abasolo; Marta Redondo; Miguel Angel Perez-Nieto; Luis Rodriguez-Rodriguez; Maria Isabel Casado; Rafael Curbelo; Juan Angel Jover Journal: Rheumatol Int Date: 2013-09-27 Impact factor: 2.631
Authors: Linda Kwakkenbos; Linda M Willems; Frank H J van den Hoogen; Wim G J M van Lankveld; Hanneke Beenackers; Toon F van Helmond; Eni S Becker; Cornelia H M van den Ende Journal: J Clin Psychol Med Settings Date: 2014-12
Authors: Shadi Gholizadeh; Sarah D Mills; Rina S Fox; Erin L Merz; Scott C Roesch; Philip J Clements; Suzanne Kafaja; Daniel E Furst; Dinesh Khanna; Vanessa L Malcarne Journal: J Rheumatol Date: 2017-04-15 Impact factor: 4.666
Authors: Erin L Merz; Vanessa L Malcarne; Scott C Roesch; Deepthi K Nair; Gloria Salazar; Shervin Assassi; Maureen D Mayes Journal: Qual Life Res Date: 2016-07-28 Impact factor: 4.147
Authors: Erin L Merz; Vanessa L Malcarne; Shervin Assassi; Deepthi K Nair; Tiffany A Graham; Brayden P Yellman; Rosa M Estrada-Y-Martin; Maureen D Mayes Journal: Arthritis Care Res (Hoboken) Date: 2014-04 Impact factor: 4.794
Authors: Linda Kwakkenbos; Erin Arthurs; Frank H J van den Hoogen; Marie Hudson; Wim G J M van Lankveld; Murray Baron; Cornelia H M van den Ende; Brett D Thombs Journal: PLoS One Date: 2013-01-11 Impact factor: 3.240
Authors: Angela Del Rosso; Svetlana Mikhaylova; Marco Baccini; Ilaria Lupi; Marco Matucci Cerinic; Susanna Maddali Bongi Journal: Biomed Res Int Date: 2013-07-29 Impact factor: 3.411